The contract for reimbursement of benefits related to α-GPC, a brain function improvement drug, was extended until March 15th. The MOHW ordered The NHIS to extend the deadline for negotiations on the Choline alfoscerate formulation on the 10th. February 10, which ordered an extension of the negotiation period, marks the end of the first negotiations for the MOHW to end negotiations and contracts for 129 pharmaceutical companies and 227 items of α-GPC(Choline alfoscerate).

On December 14, 2020, the MOHW ordered the termination of the contract for reimbursement of benefits for Choline alfoscerate by February 10 in accordance with the Rules on the Standards of National Health Insurance Medical Benefits.